Methotrexate-induced papular eruption: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
Tag: Reverted
CSV import
 
(2 intermediate revisions by the same user not shown)
Line 1: Line 1:
{{Infobox medical condition (new)
 
| name           = <!--{{PAGENAME}} by default-->
{{Infobox medical condition
| synonym        =
| name                   = Methotrexate-induced papular eruption
| image          =
| synonyms                =  
| image_size      =  
| field                  = [[Dermatology]]
| alt            =  
| symptoms               = [[Papule]]s, [[rash]], [[pruritus]]
| caption        =
| complications           =  
| pronounce      =
| onset                   =  
| specialty      = dermatology
| duration               =  
| symptoms       =
| causes                 = [[Methotrexate]]
| complications   =
| risks                   =  
| onset           =
| diagnosis               = Clinical evaluation, [[skin biopsy]]
| duration       =
| differential           = [[Drug eruption]], [[psoriasis]], [[eczema]]
| types          =  
| prevention             =  
| causes         =
| treatment               = Discontinuation of methotrexate, [[topical corticosteroids]]
| risks           =
| medication             =  
| diagnosis       =
| prognosis               =  
| differential   =
| frequency               = Rare
| prevention     =
| deaths                 =  
| treatment       =
| medication     =
| prognosis       =
| frequency       =
| deaths         =
}}
}}
'''Methotrexate-induced papular eruption''' appears in patients being treated with [[methotrexate]], such as those with rheumatic disease, presenting with [[List of cutaneous conditions|erythematous indurated papules]], usually located on the [[Proximal phalanges|proximal extremities]].<ref name="Andrews">James, William; Berger, Timothy; Elston, Dirk (2005). ''Andrews' Diseases of the Skin: Clinical Dermatology''. (10th ed.). Saunders. Page 181. {{ISBN|0-7216-2921-0}}.</ref>
{{Short description|A skin condition caused by methotrexate}}
 
==Methotrexate-induced papular eruption==
It has been suggested that it may represent a [[cutaneous small-vessel vasculitis]].<ref>{{cite journal | doi = 10.1345/aph.1K271 | pmid = 18094347 | volume=42 | issue=1 | title=Methotrexate-induced papular eruption following treatment of psoriasis |date=January 2008  |vauthors=Mebazaa A, Kenani N, Denguezli M, etal | journal=Ann Pharmacother | pages=138–41}}</ref>
'''Methotrexate-induced papular eruption''' is a [[dermatological]] condition characterized by the appearance of papules on the skin as a result of [[methotrexate]] therapy. Methotrexate is a [[disease-modifying antirheumatic drug]] (DMARD) commonly used in the treatment of various [[autoimmune diseases]] and certain types of [[cancer]].
 
==Pathophysiology==
==See also==
Methotrexate works by inhibiting the enzyme [[dihydrofolate reductase]], which is crucial for the synthesis of [[nucleotides]] and, consequently, [[DNA]] replication and cell division. This mechanism is beneficial in slowing down the rapid proliferation of cells in conditions like [[psoriasis]] and certain cancers. However, it can also affect normal skin cells, leading to adverse dermatological reactions such as papular eruptions.
*[[List of cutaneous conditions]]
==Clinical Presentation==
 
Patients with methotrexate-induced papular eruption typically present with small, raised, red or skin-colored papules. These lesions are often distributed symmetrically and can appear on the [[trunk]], [[extremities]], and occasionally on the [[face]]. The papules may be accompanied by [[pruritus]] (itching) and can vary in number and size.
==References==
==Diagnosis==
{{reflist}}
The diagnosis of methotrexate-induced papular eruption is primarily clinical, based on the patient's history of methotrexate use and the characteristic appearance of the skin lesions. A [[skin biopsy]] may be performed to rule out other conditions and to confirm the diagnosis. Histopathological examination typically shows features of a drug-induced eruption, such as [[lymphocytic infiltrate]] and [[epidermal]] changes.
 
==Management==
{{Cutaneous-condition-stub}}
Management of methotrexate-induced papular eruption involves discontinuation or adjustment of methotrexate therapy. In some cases, reducing the dose or switching to an alternative medication may be necessary. Topical treatments, such as [[corticosteroids]], can be used to alleviate symptoms. In severe cases, systemic treatments may be required.
{{External causes of morbidity and mortality}}
==Prognosis==
[[Category:Connective tissue diseases]]
The prognosis for methotrexate-induced papular eruption is generally good, especially if the offending drug is discontinued or the dose is adjusted. The skin lesions typically resolve without scarring once methotrexate is withdrawn or the dose is reduced.
{{dictionary-stub1}}
==Prevention==
{{No image}}
Preventive measures include careful monitoring of patients on methotrexate therapy, especially those with a history of drug-induced skin reactions. Regular follow-up and patient education about potential side effects can help in early detection and management of adverse reactions.
__NOINDEX__
==Related pages==
* [[Methotrexate]]
* [[Drug eruption]]
* [[Psoriasis]]
* [[Autoimmune disease]]
[[Category:Dermatology]]
[[Category:Adverse drug reactions]]
[[Category:Autoimmune diseases]]

Latest revision as of 00:11, 4 April 2025


Methotrexate-induced papular eruption
Synonyms
Pronounce N/A
Specialty N/A
Symptoms Papules, rash, pruritus
Complications
Onset
Duration
Types N/A
Causes Methotrexate
Risks
Diagnosis Clinical evaluation, skin biopsy
Differential diagnosis Drug eruption, psoriasis, eczema
Prevention
Treatment Discontinuation of methotrexate, topical corticosteroids
Medication
Prognosis
Frequency Rare
Deaths


A skin condition caused by methotrexate


Methotrexate-induced papular eruption[edit]

Methotrexate-induced papular eruption is a dermatological condition characterized by the appearance of papules on the skin as a result of methotrexate therapy. Methotrexate is a disease-modifying antirheumatic drug (DMARD) commonly used in the treatment of various autoimmune diseases and certain types of cancer.

Pathophysiology[edit]

Methotrexate works by inhibiting the enzyme dihydrofolate reductase, which is crucial for the synthesis of nucleotides and, consequently, DNA replication and cell division. This mechanism is beneficial in slowing down the rapid proliferation of cells in conditions like psoriasis and certain cancers. However, it can also affect normal skin cells, leading to adverse dermatological reactions such as papular eruptions.

Clinical Presentation[edit]

Patients with methotrexate-induced papular eruption typically present with small, raised, red or skin-colored papules. These lesions are often distributed symmetrically and can appear on the trunk, extremities, and occasionally on the face. The papules may be accompanied by pruritus (itching) and can vary in number and size.

Diagnosis[edit]

The diagnosis of methotrexate-induced papular eruption is primarily clinical, based on the patient's history of methotrexate use and the characteristic appearance of the skin lesions. A skin biopsy may be performed to rule out other conditions and to confirm the diagnosis. Histopathological examination typically shows features of a drug-induced eruption, such as lymphocytic infiltrate and epidermal changes.

Management[edit]

Management of methotrexate-induced papular eruption involves discontinuation or adjustment of methotrexate therapy. In some cases, reducing the dose or switching to an alternative medication may be necessary. Topical treatments, such as corticosteroids, can be used to alleviate symptoms. In severe cases, systemic treatments may be required.

Prognosis[edit]

The prognosis for methotrexate-induced papular eruption is generally good, especially if the offending drug is discontinued or the dose is adjusted. The skin lesions typically resolve without scarring once methotrexate is withdrawn or the dose is reduced.

Prevention[edit]

Preventive measures include careful monitoring of patients on methotrexate therapy, especially those with a history of drug-induced skin reactions. Regular follow-up and patient education about potential side effects can help in early detection and management of adverse reactions.

Related pages[edit]